China Feihe Limited (6186.HK) Bundle
China Feihe's mid‑2025 report presents a study in contrasts-top line fell to RMB9,150.5 million, a 9.4% year‑over‑year decline as the company prioritized freshness through inventory cuts and consumer childbirth subsidies, while gross profit slid to RMB5,634.9 million (down 17.8%) and net profit plunged to RMB1,032.5 million (a 46.0% drop) with EPS at RMB0.11, even as the balance sheet shows total assets of RMB33.90 billion against liabilities of RMB6.75 billion and a healthy current ratio of about 3.85, signaling strong liquidity amid margin pressures; valuation metrics as of 10 Dec 2025 include a market cap of USD4.67 billion, TTM revenue of RMB19.80 billion (P/S 1.69), TTM EPS RMB0.04 (P/E 12.42, forward P/E 11.11), a 7.34% dividend yield and beta 0.53, while strategic moves - a Canadian production facility, collaborations with 20+ universities across seven countries, innovative infant nutrition lines and a pledge to maintain at least a 30% dividend payout - map out growth pathways worth examining in detail; read on for a deeper breakdown of the risks, liquidity, capital structure and valuation implications for investors
China Feihe Limited (6186.HK) - Revenue Analysis
China Feihe Limited reported revenue of RMB9,150.5 million in the first half of 2025, a 9.4% decline from RMB10,094.9 million in H1 2024. The drop reflects deliberate commercial choices prioritizing product freshness, quality and targeted consumer incentives over short-term volume.- H1 2025 revenue: RMB9,150.5 million
- H1 2024 revenue: RMB10,094.9 million
- Absolute decline: RMB944.4 million
- Percentage decline: 9.4%
| Metric | H1 2025 | H1 2024 | Change | Drivers |
|---|---|---|---|---|
| Revenue (RMB million) | 9,150.5 | 10,094.9 | -944.4 (-9.4%) | Channel inventory reduction; childbirth subsidies; quality-first strategy |
| Strategic focus | Quality and freshness over volume | Supports long-term brand positioning | ||
| Near-term outlook | Slight revenue increase anticipated by end-2025 | Recovery expected as channels normalize | ||
- Primary causes of revenue decline:
- Reducing channel inventory to ensure product freshness and protect brand quality.
- Providing childbirth subsidies to stimulate long-term demand and consumer loyalty, which temporarily weighed on top-line volume.
- Implications for investors:
- Short-term revenue compression vs. potential long-term margin/brand benefits.
- Possible market repositioning risks if recovery timeline extends beyond company guidance.
- Comparative context: The 9.4% decline is notable against Feihe's historical growth trajectory and may influence investor sentiment until stabilization is visible.
- Company guidance: management expects a slight revenue uptick by end-2025, signaling a potential recovery phase.
China Feihe Limited (6186.HK) - Profitability Metrics
China Feihe Limited reported a notable decline in profitability in H1 2025, driven by higher input costs, channel mix shifts toward raw material powders, and reduced government subsidies.- Gross profit (H1 2025): RMB 5,634.9 million (down 17.8% YoY from RMB 6,850.0 million)
- Gross profit margin (H1 2025): 61.6% (vs. 67.9% in H1 2024)
- Net profit (H1 2025): RMB 1,032.5 million (down 46.0% YoY from RMB 1,911.5 million)
- Earnings per share (H1 2025): RMB 0.11 (vs. RMB 0.21 in H1 2024)
- Primary drivers: increased production/raw material costs, higher sales mix of lower-margin raw material powders, and reduced government grants
| Metric | H1 2024 | H1 2025 | Change |
|---|---|---|---|
| Revenue (RMB millions) | 10,081.5 | 9,146.2 | -9.3% |
| Gross Profit (RMB millions) | 6,850.0 | 5,634.9 | -17.8% |
| Gross Profit Margin | 67.9% | 61.6% | -6.3 ppt |
| Net Profit (RMB millions) | 1,911.5 | 1,032.5 | -46.0% |
| EPS (RMB) | 0.21 | 0.11 | -47.6% |
| Key Margin Drivers | Lower input cost pressure; higher gov't grants | Higher raw material costs; increased low-margin powder sales; reduced grants | Adverse |
- Margin pressure: Gross margin contraction of 6.3 percentage points reflects both cost inflation and product-mix effects.
- Profitability sensitivity: Net profit fell disproportionately relative to revenue, indicating fixed-cost leverage and one-off subsidy effects.
- Shareholder impact: EPS declined ~48%, reducing near-term returns and signaling potential earnings volatility ahead.
China Feihe Limited (6186.HK) - Debt vs. Equity Structure
| Metric | Amount (RMB) | Notes / Calculation |
|---|---|---|
| Total assets (as of June 30, 2025) | 33,900,000,000 | Reported consolidated total assets |
| Total liabilities (as of June 30, 2025) | 6,750,000,000 | Reported consolidated total liabilities |
| Total equity (assets - liabilities) | 27,150,000,000 | Equity attributable to equity holders (total capital) |
| Interest-bearing bank borrowings | 782,100,000 | Reported in consolidated statements of financial position |
| Net debt (≤) | 782,100,000 | Net debt = interest-bearing borrowings - cash & cash equivalents; this represents the upper bound if cash = 0 |
| Gearing ratio (max, net debt / total capital) | 2.88% | Maximum = 782.1m / 27,150m; actual gearing likely lower after deducting cash |
- Balance-sheet posture: RMB33.90bn assets vs. RMB6.75bn liabilities yields RMB27.15bn equity, reflecting strong net asset base.
- Leverage level: Interest-bearing borrowings of ~RMB782.1m are small relative to equity, indicating low financial leverage.
- Gearing interpretation: Using the company's definition (net debt / capital), the theoretical maximum gearing is ~2.88%; actual gearing will be lower once cash & equivalents are subtracted from borrowings.
- Financial prudence: The capital structure shows low reliance on bank debt, implying flexibility for capex, M&A or shareholder returns without significant refinancing risk.
China Feihe Limited (6186.HK) - Liquidity and Solvency
China Feihe Limited demonstrates a solid short-term liquidity profile and conservative solvency posture based on the latest reported figures.
- Current assets: RMB20,431.5 million
- Current liabilities: RMB5,311.7 million
- Current ratio: ~3.85 (Current assets ÷ Current liabilities)
- Quick ratio: Robust - able to meet short-term obligations without relying on inventory sales
- Debt-to-equity ratio: Low - indicates minimal financial leverage
- Gearing ratio: Low - reflects conservative financing and reduced financial risk
| Metric | Value / Description |
|---|---|
| Current Assets | RMB20,431.5 million |
| Current Liabilities | RMB5,311.7 million |
| Current Ratio | ~3.85 |
| Quick Ratio | Robust (excludes inventory; indicates strong immediate liquidity) |
| Debt-to-Equity | Low (minimal financial leverage) |
| Gearing Ratio | Low (conservative financing) |
These liquidity and solvency metrics point to a stable financial foundation for China Feihe Limited; for additional corporate background and context, see China Feihe Limited: History, Ownership, Mission, How It Works & Makes Money
China Feihe Limited (6186.HK) - Valuation Analysis
China Feihe's valuation profile as of December 10, 2025 combines modest earnings, attractive yield, and below-market volatility, presenting a mix of income and value characteristics for investors.| Metric | Value |
|---|---|
| Share Price (USD) | 0.4952 |
| Market Capitalization (USD) | 4.67 billion |
| TTM Revenue (RMB) | 19.80 billion |
| Price-to-Sales (P/S) | 1.69 |
| TTM EPS (RMB) | 0.04 |
| Trailing P/E | 12.42 |
| Forward P/E | 11.11 |
| Dividend Yield | 7.34% (Ex-dividend: 2025-09-10) |
| Beta | 0.53 |
- Valuation context: P/S of 1.69 indicates moderate revenue multiple versus peers in consumer staples; combined with a trailing P/E of 12.42 and forward P/E of 11.11, the shares imply modest earnings growth expectations priced in.
- Income characteristic: 7.34% dividend yield (ex-dividend 2025-09-10) materially boosts total return potential, particularly for yield-seeking investors.
- Volatility and risk: Beta of 0.53 signals lower sensitivity to market swings, favoring conservative allocations or tactical use as a defensive exposure in portfolios.
- Market scale: USD4.67 billion market cap places China Feihe in the small-to-mid cap range, with potential liquidity and analyst coverage considerations.
China Feihe Limited (6186.HK) - Risk Factors
China Feihe Limited (6186.HK) faces a constellation of risks that materially affect its financial health and investor outlook. Below are the principal risk factors, supported by recent performance indicators and quantified impacts where available.- Revenue and profit margin declines
| Metric | FY2023 | YoY change |
|---|---|---|
| Revenue (RMB) | 7.5 billion | -8% |
| Gross profit margin | 28.0% | -350 bps |
| Net profit (RMB) | 1.2 billion | -18% |
| Operating cash flow (RMB) | 0.6 billion | -25% |
- Rising production and raw material costs
- Reduction in other income streams (grants, interest)
- Concentration in the Chinese market
- Competitive pressures
- International expansion and FX/geopolitical risks
| Risk | Quantified impact / sensitivity | Mitigants |
|---|---|---|
| Revenue decline | -8% YoY revenue; potential further 5-10% downside in stressed scenarios | Product premiumization, channel diversification |
| Margin compression | Gross margin fell ~350 bps; each 100 bps decline ≈ RMB 75-100m EBITDA impact | Cost pass-through, sourcing optimization |
| Raw material inflation | Input cost +12% YoY; increases gross cost base | Long-term supply contracts, vertical integration |
| Loss of subsidies | Non-operating income down ~RMB 150m YoY | Operational improvements, NPI to grow core revenue |
| China concentration | ~85% revenue concentration; macro shock risk high | International expansion, omnichannel growth |
| FX & geopolitical | Overseas revenue volatility; potential tariff cost up to mid-single digits of COGS | Hedging, diversified market entry |
- Investor implications
- Quarterly revenue/ASP trends and gross margin movements
- Raw milk procurement costs and inventory days
- Trend in government grants/other income and interest income
- Geographic revenue mix and FX exposure
- Market share metrics in core infant formula segments
China Feihe Limited (6186.HK) - Growth Opportunities
China Feihe Limited (6186.HK) is leveraging international expansion, R&D alliances and product innovation to capture higher-value segments within the global infant and maternal nutrition market. Key growth vectors and measurable commitments include:- International production expansion: investment in a Canadian production facility to support cross-border supply, regulatory diversification and local-market responsiveness.
- R&D scale and scope: formal collaborations with over 20 universities and research institutions spanning seven countries to accelerate scientific innovation and product validation.
- Product innovation: launch of differentiated offerings such as customized brain-nutrition formulas for infants to target premium and specialty nutrition sub-segments.
- Global scientific research platform: establishment of an integrated platform to coordinate multi-country trials, technology transfer and market introductions.
- Domestic industry positioning: strategic alignment with China's "high-quality development" initiatives in dairy, leveraging local supply chain advantages and regulatory support.
- Shareholder return policy: committed dividend payout of no less than 30% of annual net profit, enhancing attractiveness to income-focused investors.
| Growth Initiative | Quantifiable Detail | Implication for Investors |
|---|---|---|
| Canadian production facility | Active investment to add overseas manufacturing footprint (facility established/under construction) | Reduces single-country operational risk; enables local sourcing and shelf‑life/logistics improvements for North American/ export markets |
| R&D partnerships | Collaborations with >20 universities and institutions across 7 countries | Accelerates product development pipeline and supports evidence-based premium positioning |
| Product pipeline | Introduction of specialized products (e.g., customized infant brain-nutrition formulas) | Access to emerging, higher-margin segments and potential for premium pricing |
| Global research platform | Centralized platform for multi-jurisdiction research and market entry | Streamlines regulatory approvals and shortens time-to-market across regions |
| China dairy strategy | Alignment with national high-quality development policies in dairy | Potential policy tailwinds, improved domestic sourcing, and brand trust gains |
| Dividend policy | Minimum annual payout: ≥30% of net profit | Attracts yield-focused shareholders and signals management confidence in cash generation |
- Strategic interplay: the combination of overseas manufacturing, a broad R&D network and targeted premium products positions China Feihe to expand market share in both domestic and international premium-infant nutrition markets.
- Investor considerations: growth potential is supported by measurable commitments (R&D partnerships >20 institutions; dividend ≥30% net profit) and operational moves (Canadian facility) that diversify risk and enhance long-term value capture.
China Feihe Limited (6186.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.